AHR and polycystic ovary syndrome: These axes converge to improve tissue-specific PCOS features: ovarian androgen synthesis (HDAC/NF-κB inhibition), hepatic IR (FXR/PI3K-Akt), and ovulatory function (AhR-mediated Treg/Th17 balance).